Microbiome
Innovating to Target the Microbiome for Human Health
Servatus
PAO-11-24-RTM-15Apr 08, 2025
Microbiome
Harnessing the Human Microbiome: 30 Years of Discovery and Innovation in Biopharma
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-02Mar 02, 2025
LBPs
Exploring the Microbiome with Servatus
Servatus
PAO-11-24-RTM-14Nov 18, 2024
Advanced Therapies
A New Vision for Progressing Advanced Therapies
Nathaniel Youndt
ReciBioPharm
PAO-10-24-CL-13Oct 25, 2024
Microbiome
Modifying the Gut Microbiome to Improve CAR-T, HSCT, and Other Therapeutic Responses
Stacy Burns-Guydish, Ph.D.
List Labs
PAO-10-23-CL-07-33Nov 01, 2023
Microbiome Therapeutic Innovation
Unleashing the Power of the Microbiome: Advancements, Challenges, and the Therapeutic Future
Stacy Burns-Guydish, Ph.D.; Gary Henderson
List Labs
PAO-03-23-CL-08Apr 04, 2023
Microbiome-Based CDMO
Expanding a Leadership Position in Microbiome-Based Contract Development and Manufacturing
Stacy Burns-Guydish, Ph.D.; Jonathan Yongwan Jo; Gary Henderson; Michael Kimble
List Labs
PAO-11-022-CL-13Dec 13, 2022
Diabetes Research
Composition of Gut Microbiome Predicts the Onset of Type 2 Diabetes
University of Turku
PR-M02-22-13Feb 16, 2022
Live Biotherapeutic Products
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Aaron B. Cowley, Ph.D.; Nicole O'Brien, Ph.D.
ReciBioPharm
PAO-09-21-CL-11Sep 28, 2021
Live Biotherapeutic Products
Design Considerations for Live Biotherapeutic Product Facilities Working with Spore-Forming Bacteria
Aaron B. Cowley, Ph.D.; Judith Bodette; Brian Duffy
ReciBioPharm
PAO-06-21-CL-10Jun 25, 2021
Live Biotherapeutic Products
Framing the Narrative on CMC Development for Microbiome Therapeutics
Aaron B. Cowley, Ph.D.; Melanie Cerullo; Jeff Heiser
ReciBioPharm
PAO-06-21-CL-05Jun 14, 2021
Microbiome
Understanding the Link Between Gut Health and Disease
Dr. Sabine Hazan
ProgenaBiome
PTV-05-21-CL-004May 27, 2021
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
Pharma's Almanac
PAO-03-21-NI-01Mar 16, 2021
Manufacturing Facility
Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and Closes Series B Equity Financing
Arranta Bio
PR-M03-21-002-1066Mar 08, 2021
Corporate Social Responsibility
Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity
Susan Surabian; Melanie Cerullo
Arranta Bio
PAP-Q4-20-CL-002Dec 09, 2020
The Future of Healthcare
How Does Arranta Bio Envision the Future of the Pharma/Biopharma Industry?
Arranta Bio
PAP-Q4-20-RT2-007Dec 09, 2020
Gene Editing
Enhancing Human Gut Tissue Models through Gene Editing
Scott Magness, Ph.D.
Altis Biosystems
PAO-11-20-CL-03Nov 30, 2020
Microbiome
Evaluating Microbiome Therapies with Intestinal Cell Models
Scott Magness, Ph.D.
Altis Biosystems
PAO-10-20-CL-02Oct 22, 2020
Microbiome CDMO
Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products
Aaron B. Cowley, Ph.D.
ReciBioPharm
PAP-Q3-20-CL-004Sep 29, 2020
Design Logic
Experience to Solve Your Microbiome Challenges
Nice Insight
PAP-Q3-20-NI-010Sep 29, 2020